PF-Atlas › Clinical Trials › NCT01910415

Phase 1, QT/QTC Interval Study in Healthy Subjects

Lumacaftor · Phase 1

Registry ID

NCT01910415

Phase

Phase 1

Status

Completed

Drug / intervention

Lumacaftor

Sponsor

Vertex Pharmaceuticals Incorporated

Start

2013-06

About this trial

Lumacaftor is evaluated in NCT01910415, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.

View NCT01910415 on ClinicalTrials.gov →

Explore related

All Lumacaftor trials All IPF trials

Related trials

Lumacaftor — NCT01225211

Medical disclaimer. This page summarizes public trial data for NCT01910415 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.